Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.
Sebastian C. Schmid, MD
Advertisement
Articles by Sebastian C. Schmid, MD
Sebastian C. Schmid, MD, discusses the rationale for the phase 2 RACE IT trial in urothelial carcinoma.
Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.
Advertisement
Latest Updated Articles
Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial CarcinomaPublished: December 1st 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5